NEW YORK (dpa-AFX) – The start of the corona vaccinations and the prospect of a billion-dollar aid package for the US economy drove share prices on Wall Street at the beginning of the week. The Dow Jones Industrial (Dow Jones 30 Industrial) advanced on Monday by 0.80 percent to 30,288 points. For another record high of the stock market barometer, there was not much trade missing.
The market-wide S&P 500 climbed 0.93 percent to 3698 points. For the technology-heavy selection index NASDAQ 100 it went up by 1.2 percent to 12,523 points. These two indices also have the prospect of historic highs.
In the USA, a bipartisan agreement on an economic stimulus package worth around 900 billion US dollars could be reached this Monday. The optimists about the Brexit trade pact also continue to see good opportunities for a trade pact between the British and the European Union, as talks about a deal are still ongoing.
In addition, after an emergency approval in the United States, vaccinations against the coronavirus began with a vaccine from BioNTech and Pfizer. The shares of the two companies could no longer fuel that on Monday: The Nasdaq-listed Biontech papers fell by 4 percent and Pfizer by 0.4 percent. Both stocks had risen sharply recently.
The papers from CureVac, however, rose by almost 6 percent after the Tübingen Biotech-Company announced the start of a pivotal clinical trial for a corona vaccine. The first results are expected at the end of the first quarter of 2021.
But not only vaccine issues moved the pharmaceutical industry this Monday. A billion-dollar takeover is also in focus: The British drug manufacturer AstraZeneca wants to buy the US competitor Alexion (Alexion Pharmaceuticals) for a total of 39 billion US dollars. As a result, Alexion shares jumped around 30 percent.
A buy recommendation by the UBS bank for McDonald’s (McDonalds) caused the fast food chain’s price to rise by 2.7 percent./bek/mis
–
TRADE FOREIGN EXCHANGE WITH UP TO LEVER 30 NOW
Trade forex with high leverage and small spreads. With only € 100.00 you can benefit from the effect of € 3,000 in capital.
–
76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford the high risk of losing your money.
–
– .
